Navigation Links
VIA Pharmaceuticals Secures Financing Up to $10.0 Million
Date:3/12/2009

n, upon completion of a financing with gross proceeds (as defined in the Loan Agreement) in excess of $20.0 million.

In connection with the loan, the Company granted the Lender warrants to purchase an aggregate of 83,333,333 shares of the Company's common stock at $0.12 per share (the "Warrants"). The Warrants vest based on the amount of borrowings under the loan and the passage of time as set forth in the Loan Agreement. Based on the $2.0 million borrowing at closing, the Warrants are currently vested with respect to 8,333,333 shares and will vest with respect to an additional 8,333,333 shares 45 days after closing if certain conditions are met as provided for in the Loan Agreement. The Warrants will vest with respect to additional shares in connection with each subsequent borrowing in accordance with the terms of the Loan Agreement.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. In addition, VIA's pipeline of drug candidates includes other compounds to address other underlying causes of cardiovascular disease: high cholesterol, diabetes and inflammation. For more information, visit: http://www.viapharmaceuticals.com.

Forward Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual re
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
2. XTL Biopharmaceuticals Ltd. Extraordinary General Meetings Postponed Until March 18, 2009
3. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
4. Onyx Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
5. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
6. Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
7. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
8. AcelRx Pharmaceuticals Hires Mark Evashenk as Vice President of Clinical Operations
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 29, 2015 Research ... addition of the "Biotechnology for the Non-Biotechnologist" ... for the Non-Biotechnologist, ideal for non-Scientists and Scientists ... and potential of biotechnology. Ideal for ... theory, principles, techniques, and potential of biotechnology ...
(Date:7/6/2015)... 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: ... Novella Clinical (Novella), to conduct the phase ... diagnosed glioblastoma. Novella is a full-service, global clinical research ... mid-sized oncology companies. The ICT-107 phase 3 trial will ... Europe and Canada ...
(Date:7/3/2015)... July 3, 2015 ... verkossa osoitteessa  http://www.openinnovationinscience.at Wienissä ... in Science" -jatkokoulutusohjelmaan 22.7.2015 asti.  ... (LBG) tekemän, kansainvälisiä tutkijoita ja ... kaksi suurinta haastetta ovat kannustimien ...
(Date:7/3/2015)... , July 3, 2015 ... till 22 september 2015 på  http://www.openinnovationinscience.at ... Innovation in Science" som hålls i ... en färsk undersökning med internationella forskare och ... (LBG) är hälsovetenskapens två största utmaningar bristen ...
Breaking Biology Technology:ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 2Maailman ensimmäinen tiedemiesten koulutukseen suunniteltu avoimen innovaation ohjelma käynnistyy 3Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... Netsmart, the leading provider of clinical solutions for ... Netsmart clients have so far received or are on ... funds for the Meaningful Use of an Electronic Health ... Use funding commitments announced to date for behavioral health ...
... 2011  Brinson Patrick Securities Corporation, a boutique investment bank specializing ... in the U.S. raised $25 million through activity of nine ... this year. While the data represent a ... life sciences sector compared to the second quarter of 2011, ...
... , Dr. Vivek Desai, MD, Hosmac India Pvt. Ltd. ... Clear winner under Healthcare & Biotech Category ... his hat of success at the felicitation ceremony of ,ET ... Managing Director, Hosmac India Pvt. Ltd. is now doubly charged ...
Cached Biology Technology:Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments 2Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments 3Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments 4Netsmart Clients to Receive Nearly $2 Million in Meaningful Use EHR Incentive Payments 5At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter 2At-the-Market Offerings (ATM) of Life Sciences Companies Perform Well in Weak Follow-on Financing Environment of Third Quarter 3Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 2Sweet Success for Hosmac India Pvt. Ltd. at ET NOW-IndiaMART Leaders of Tomorrow Awards 2011 3
(Date:6/17/2015)... Germany , June 17, 2015 ... Standard: QIA) today launched new Investigator ® STR assay ... the United States . The new genetic ... key genomic markers (short tandem repeats or STRs) for DNA ... evaluate the quality of DNA in each sample, a novel ...
(Date:6/16/2015)... Sweden , June 16, 2015 ... all touch fingerprint sensors in the company,s portfolio from one ... Deliveries are planned to mainly take place during the third ... in Asia . Jörgen Lantto, ... evidence of    the   growing interest from smartphone OEMs ...
(Date:6/12/2015)... , June 12, 2015  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... its patent to electronically capture, analyze and identify ... facial recognition methods. This system can: ... by an enrollment and subsequent sign-on process is ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Securus Announces Patent Issued for Authorized Presence Verification During Video Visitation 2
... While some published research has hinted at the connection ... among young, athletic African-American males, which was initially observed ... study with the first sizeable patient series definitively confirms ... The sickle cell trait, for which all U.S. African ...
... time, scientists have identified tropical and subtropical species of ... traveled thousands of miles on Atlantic currents and ended ... warm water, not as a direct result of overall ... arctic waters are warming rapidly, and such pulses are ...
... Gould once asked: If we rerun the tape of life, ... scientists have questioned whether evolution is predictable, or whether chance ... July 23 in the Proceedings of the National Academy ... that developed resistance to a powerful plant toxin, the same ...
Cached Biology News:Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 2Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 3Tropical plankton invade Arctic waters 2Tropical plankton invade Arctic waters 3Tropical plankton invade Arctic waters 4Tropical plankton invade Arctic waters 5Same adaptations evolve across different insects 2
... ester can be used to ... The covalently bound acridinium NHS ... the presence of hydrogen peroxide. ... be used as a detection ...
... up to 6 strain chambers with precise uniaxial ... design ensures that cells grow over long periods ... This unit allows you to control the frequency ... unique strain settings. The instrument fits in a ...
... a novel procedure for the uniform amplification ... genome DNA from small samples. This method ... and highly reproducible amplification and labeling procedure ... REPLI-g Mini Kit module (QIAGEN) and a ...
... using PULSin may be superior to transfection ... traditional transfection, with PULSin you can study ... time course of proteins in cells. Likewise, ... information than traditional RNA interference experiments. ...
Biology Products: